

MBSZ közgyűlés

elnöki beszámoló

2025. 05. 27.

2024: The Bifurcated Biotech Ecosystem


Winners:

- **Experienced leadership and proven platforms** dominate, especially in hot therapeutic areas (obesity, neurology, immunology, oncology).
- **Mega-rounds** abound for the elite: >\$100M Series A rounds are increasingly common, especially for companies with in-licensed clinical assets.
- **Corporate VC and big pharma** are filling in funding gaps, targeting assets that align with their pipeline needs.

Losers:

- **Early-stage biotechs** without compelling data or experienced teams are struggling.
- **Middle-stage companies** (post-seed, pre-proof-of-concept) are often stranded: too far from clinical de-risking, but too expensive post-pandemic.
- **Cell and gene therapy** is out of favor due to complex manufacturing and commercialization risks.

Average venture funding round size reaches an all-time-high in the first half of 2024.





• **VCs are consolidating bets** on fewer, larger rounds, prioritizing quality over quantity.


New VC fundraises are recovering but still below 2021's bubble levels — \$20B expected in 2024 vs. \$31B in 2021.

Series A rounds average \$80M in 2024 — double 2019's average. A full quarter now exceed \$100M.

Seed rounds are also inflating, becoming longer, more capital-intensive, and more selective.



Total amount raised (\$ millions)



Hot areas attracting capital:

- **Antibody–Drug Conjugates (ADCs)** — Massive M&A activity and late-stage data drive investor interest.
- **Radioligand Therapies (RLTs)** — Unique radiological mechanisms and positive trial results attract big rounds.
- **AI-driven drug discovery** — Tech investors are flooding in, fueling the largest biotech seed/A rounds ever seen (e.g., \$1B to Xaira, \$142M to EvolutionaryScale).

Cold or cooling areas:

- **Cell and Gene Therapy (CGT)** — Down across metrics. Progress lags in manufacturing, scalability, and commercial viability.

THE NOBEL PRIZE
IN PHYSICS 2024



John J. Hopfield

Geoffrey E. Hinton

“for foundational discoveries and inventions
that enable machine learning
with artificial neural networks”

THE ROYAL SWEDISH ACADEMY OF SCIENCES



Conclusion

Biotechs

must align with big pharma needs, demonstrate clinical proof early, and be led by seasoned teams.

Investors

must be selective and patient, balancing short-term exits with long-term platform bets.

After obesity drugs' success, companies rush to preserve skeletal muscle

A growing number of companies are testing muscle-building agents to counter the side effects of dramatic weight loss and potentially to preserve lean muscle into old age.

By Carrie Arnold

Even as obesity treatments Ozempic and Mounjaro continue their surge in popularity, drug hunters are asking whether it is possible for people to lose weight on these glucagon-like peptide-1 (GLP-1) agonists without losing muscle. Drug candidates originally designed to build, preserve or regenerate skeletal muscle for treating muscle atrophy in degenerative conditions or ageing are now being tested in combination with GLP-1 agonists [used for obesity](#) to spare lean muscle.

One such biotech is BioAge Labs. In February, the company announced a \$170-million series D financing, which will allow it to combine its apelin receptor agonist azel-



Skeletal muscle takes a hit during weight loss. To reduce the impact on muscle mass, biotechs are pairing obesity drugs with exercise mimetics.




🕒 SEPTEMBER 13, 2024

Scientists develop super golden lettuce that's richer in vitamin A

by Technical University of Valencia

👍 Editors' notes



Higher-light treatment increases β-carotene contents and bioaccessibility in lettuce leaves. Romaine lett...

A research group has developed an innovative method for the biofortification of leaves and other green plant tissues, increasing their content of healthy substances such as beta-carotene, the main precursor of vitamin A in the human diet.

**European
Innovation
Scoreboard
2024**



Figure 30: Innovation performance of the EU and its global competitors






Figure 3: Innovation performance change from 2017 to 2024 - EU versus global competitors




Note: Performance change is measured as the difference between 2024 and 2017 scores, relative to that of the EU in 2017. Due to limited data availability for global competitors, scores are calculated using a smaller set of indicators.

Figure 26: Innovation performance of the EU Member States and neighbouring countries (bar chart) (2024 vs 2023)



Note: All performance scores are relative to that of the EU in 2017. Coloured bars show countries' performance in 2024, using the most recent data for 32 indicators. The vertical bars show performance in 2023, using the next most recent data.

Figure 5: Innovation performance of the EU Member States



Note: Administrative boundaries: © EuroGeographics © UN-FAO © Turkstat. The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the European Union.

Figure 7: Innovation performance change for the EU Member States (2024 vs 2017)



Figure 20: Innovation performance of the innovation groups per dimension





Figure 28: Performance of EU Member States and neighbouring countries per indicator in 2024, compared to the EU average in 2024



Napirendi pontok

- MBSZ mérleg 2024
- Új generáció az MBSZ-ben: bemutatkozás és célok
- Felügyelőbizottsági poszt




Az MBSZ 2024. évi egyszerűsített éves beszámolójának fő sarokszámai

- **Összes bevétel:** 3.640.000 Ft
- **Összes ráfordítás:** 1.770.000 Ft
- **Adózás előtti eredmény:** 1.870.000 Ft
- **Tárgyévi eredmény:** 1.870.000 Ft

- **Befektetett eszközök:** 0.0 Ft
- **Forgóeszközök:** 6.573.000 Ft
- **Eszközök összesen:** 6.573.000 Ft
- **Saját tőke:** 6.420.000 Ft
- **Kötelezettségek:** 153.000 Ft
- **Források összesen:** **6.573.000 Ft**

Napirendi pontok

- MBSZ mérleg 2024
- Új generáció az MBSZ-ben: bemutatkozás és célok
- Felügyelőbizottsági poszt



Az MBSZ megújulásának tervei és lehetőségei

Kiss Benjamin

Sepsi Zita

Célkitűzések

- Alapszabályban megfogalmazott célok

A társadalmi szervezet célja elsődlegesen az, hogy összefogja az országban a biotechnológiában dolgozó, a biotechnológiát mint tudományt szolgáló személyeket, tudományos intézményeket, csoportokat, gazdasági társaságokat, ismeretterjesztést valósít meg, tanfolyamokat szervez, bekapcsolódik az információs és felvilágosító programokba, segíti a szakmában dolgozók és a kívülállók tájékoztatását, felveszi a kapcsolatot tudományos szervezetekkel és közintézményekkel, rendszeres kiadványokkal tájékoztatja az érdeklődőket működéséről.

- Az eredeti célok eléréséhez szükséges szervezeti működés kialakítása, amelyhez változásra van szükség

Szervezeti példák



To this end, the Swiss Biotech Association is dedicated to supporting Swiss biotech companies through the following:

• Nemzetközi példák:

- Swiss Biotech Association – 561 tag
- French Biotech Association – 700 tag
- BIO Deutschland – 321 tag

Közelebbi példa:

- Biotech Austria – 60 tag
- Czech Bio – 15 tag

Developing favorable and competitive framework conditions

- Creating awareness of the biotech industry's needs and interests with policy makers
- Advocating a competitive tax system alongside lean and pragmatic regulations
- Fostering life science education, technology transfer and intellectual property

▲ Legal framework and policies in Swiss biotech

Attracting talent, know-how and financial resources to drive innovation and growth

- Promoting and facilitating access to funding opportunities
- Connecting investors and attractive biotech investment opportunities
- Facilitating access to national and international talent

📺 Swiss Biotech Ventures platform

🎓 Swiss Biotech Association Academy

📄 Open job listings

👤 Swiss Biotech Orbit platform: Match talents and jobs

Fostering networking through strategic, national and international partnerships

- Connecting industry stakeholders and life science clusters
- Organizing and co-promoting national and international life science events
- Providing access to privileged information through industry platforms and working groups

🗓️ Events

🏠 Offline networking platforms

🗨️ Online communities

👥 Our partners

🌐 Global Village

Promoting the accomplishments of the Swiss biotech industry

- Disseminating the value-creation of Swiss biotech companies
- Visualizing the diversity and competitiveness of Swiss biotech companies
- Presenting innovative products and technologies and their contribution to quality of life

📖 Swiss Biotech Directory

★ Swiss Biotech Success Stories

📰 Swiss Biotech Report

📰 Industry news

📧 Newsletter

Fejlesztési ötletek és programok

1. Program tervek
2. Szervezeti működést érintő tervek
3. Távlati, hosszú távú tervek

Program tervek

Magyar Biotechnológiai Szövetség tagtoborzó rendezvénye **2025. november – december**

Cél:

- Felhívni a figyelmet a szervezetre és a benne lévő potenciálra
- Potenciális új tagok megkeresése, régi tagok aktivitásának növelése
- „A változás előszele” – a szövetség aktív munkájába való lehetőség bemutatása

Tematika:

- Nagyobb hírnévvel rendelkező magyar tudósok/vállalkozók meghívása
- Akadémiai kutatócsoportok meghívása
- Hallgatók meghívása – utánpótlás nevelés

Forrás:

- Meglévő MBSZ vagyon
- Céges támogatások

Program tervek

Hungarian Biotech Days – 2026-ban lenne az első

- Az ipari szereplők összehozása, lehetőség b2b találkozókra
- Nemzetközi partnerek/potenciális partnerekkel való találkozási lehetőség
- Akadémiai kapcsolatok erősítése/kialakítása

Tematika:

- Ipari szereplők bemutatkozása – tudományos problémák
- Nagyobb hírnévvel rendelkező magyar tudósok/vállalkozók meghívása
- Akadémiai- ipar együttműködéseket elősegítő programok

Forrás:

- Céges támogatásokból
- Potenciális állami források – nemzetgazdasági érdek
- Potenciális EUs források – Enterprise Europe Network, EIT Health stb.

Szervezeti működést érintő tervek

Tagok igényeinek felmérése a szervezet részéről – 2025 végéig

- Mire lenne igényük?
- Milyen programokon vennének részt szívesen?
- Milyen ügyekben lenne szükségük érdekképviselőre?

Érdekképviselői kapcsolatok újraindítása a kormányzat felé

- Szükséges, hogy a szervezet működjön és látszódjon – vannak rendezvények, aktív a tagság
- Iparági körkép – látszódjon mekkora iparágat képvisel a szervezet

Szervezeti működést érintő tervek

Online jelenlét erősítése

- Honlap fejlesztése – később
- LinkedIn – egyéb közösségi média felületek
- Rendszeres hírlevél

Tagnyilvántartás, számlázás online

- Online számlázás (számlázz.hu)
- A tagok egymás számára elérhető elérhetőségei – email, telefon

Ügyvezetői pozíció kialakítása az alapszabályban

- 2026-tól a titkár helyett ügyvezető/társügyvezetők
- Elnökség specializációja különböző feladatokra – külkapcsolatok, kormányzati kapcsolattartás, rendezvények stb.

Távlati, hosszú távú tervek

- Érdekképviselés erősítése – jobb kormányzati kapcsolatok
- Bio-manager képzés újraindítása
- Aktív részvétel nemzetközi nagy rendezvényeken (újra) – saját stand
- Start-upok segítése
- Információs kiadványok
 - biotech szektor átvilágítás/elemzés
 - projektgyűjtemény (potenciális befektetők, együttműködési lehetőségek)

Költségvetési terv


- Működési költségek fedezése a tagdíjakból
- Rendezvények/programok támogatása külső forrásból – állami/EUs
- Management fizetése

Income statement

In CHF	2024		2023	
	Expenses	Income	Expenses	Income
Membership fees		1,073,000		928,000
International projects		0		2,929
National projects		1,655,238		1,085,780
Website & community platform		1,600		1,400
Swiss Biotech Success Stories		5,000		13,000
Swiss Biotech Report		58,000		58,000
Swiss Biotech Directory		19,110		23,870
Increase/decrease bad debt provision		-5,000		-2,000
Total income		2,806,948		2,110,979
Fees to other associations	51,977		25,476	
International projects	69,235		60,882	
National projects	1,594,422		1,153,021	
Swiss Biotech Success Stories	10,097		15,615	
Decrease tied capital "Swiss Biotech Success Stories"	-3,000		-2,000	
Swiss Biotech Report	76,174		73,079	
Swiss Biotech Directory	29,889		32,150	
Website & community platform	130,440		82,735	
Association activities expense	1,959,234		1,440,958	
Management fees ¹	376,143		329,548	
Accounting & member support	240,018		167,399	
Office rent & administration	28,635		32,436	
Consulting	23,279		7,398	
Public relations	122,748		112,652	
Other operating expenses	790,823		649,434	
Financial income result		12,624		8,943
Expenses from previous reporting period		132		0

Honlap példák

Swiss Biotech



Log in or Register

Industry news

Filter news

Subscribe to our newsletter

Swiss Biotech Report 2025 highlights sector's continuing resilience through commitment to international alliances

May 6, 2025

Swiss Biotech Association

Beware of fraudulent emails impersonating the Swiss Biotech Association

October 8, 2024

Swiss Biotech Association

SIX Swiss Exchange talks to: Basilea on how it strengthened its market position in 2024

Christian Moser Nikles, Patent Expert & Christel Aebischer, Patent Expert | Swiss Federal Institute of Intellectual Property

May 5, 2025

SIX

Building the future of healthcare: Switzerland's key role in facilitating Johnson & Johnson's global alliances

Sirpa Tsimal, Director Investment Promotion | Switzerland Global Enterprise

GET THE INSIGHT Swiss Biotech Report 2025

Read online

THE LEADING SWISS BIOTECH DIRECTORY 2025

Get it


Download now

OUR ANNUAL REPORT IS HERE Have a look

Download PDF

JOIN OUR ASSOCIATION Become a member

Checkout benefits



Log in or Register

Swiss Biotech Association

Mission & services | Members | Academy | Insight Events | Partners | Team | Media

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

The central resource for the Swiss biotech industry

More than 25 years after its foundation, the Swiss Biotech Association has become a strong voice for the biotech industry. We are committed to creating and maintaining platforms that benefit all Swiss biotech companies in financing and partnering, search for talent and in education, branding, and networking. We unite people to collaboratively shape the ideal framework conditions for a vibrant Swiss biotech community and beyond.


Our annual report

The Swiss Biotech Association is the central resource for the Swiss biotech industry. Checkout our annual report, outlining our activities.

The Swiss Biotech Association development

Development in numbers in 2024





Log in or Register

The Swiss Biotech Association is a non-profit, member-driven organization representing the interests of the Swiss biotech industry. Swiss biotech companies are leading the way in developing and commercializing innovative medicines, diagnostics, healthcare treatments, services and enabling technologies.

Our core objective is to ensure that the value generated by the Swiss biotech industry continues to grow and that the industry contributes to the well-being of the socio-economic ecosystem thereby enabling Switzerland to be a key player at the forefront of bioscience innovation.

To this end, the Swiss Biotech Association is dedicated to supporting Swiss biotech companies through the following:

Developing favorable and competitive framework conditions

- Creating awareness of the biotech industry's needs and interests with policy makers
- Advocating a competitive tax system alongside lean and pragmatic regulations
- Fostering life science education, technology transfer and intellectual property

Fostering networking through strategic, national and international partnerships

- Connecting industry stakeholders and life science clusters
- Organizing and co-promoting national and international life science events
- Providing access to privileged information through industry platforms and working groups

Legal framework and policies in Swiss biotech

- Events
- Offline networking platforms
- Online communities
- Our partners
- Global Village

Attracting talent, know-how and financial resources to drive innovation and growth

- Promoting and facilitating access to funding opportunities
- Connecting investors and attractive biotech investment opportunities
- Facilitating access to national and international talent

Promoting the accomplishments of the Swiss biotech industry

- Disseminating the value-creation of Swiss biotech companies
- Visualizing the diversity and competitiveness of Swiss biotech companies
- Presenting innovative products and technologies and their contribution to quality of life

- Swiss Biotech Ventures platform
- Swiss Biotech Association Academy
- Open job listings
- Swiss Biotech Orbit platform: Match talents and jobs
- Swiss Biotech Directory
- Swiss Biotech Success Stories
- Swiss Biotech Report
- Industry news
- Newsletter

France Biotech

france biotech
biotech | medtech | e-santé | IA
LES ENTREPRENEURS DE LA HEALTHTECH

France Biotech accompagne l'innovation santé

Accès adhérent

La Healthtech en France

Communiqués de Presse

Tous les communiqués →

Toutes les catégories

22^e EDITION PANORAMA FRANCE HEALTHTECH 2024

AlzProtect

La plateforme d'essai clinique de phase 2 sur la paralysie supranucléaire progressive annonce la sélection d'AADvac1 et de AZP2006 pour ses

france biotech
BIOTECH | MEDTECH | E-SANTÉ | IA
LES ENTREPRENEURS DE LA HEALTHTECH

France Biotech, fondée en 1997, est une association indépendante qui fédère les entrepreneurs de l'innovation dans la santé et leurs partenaires experts.

Animateur de l'écosystème de l'innovation en santé et interlocuteur privilégié des pouvoirs publics, France Biotech contribue à relever les défis du secteur HealthTech et à proposer des solutions concrètes, en termes de compétitivité et d'attractivité, par l'intermédiaire de ses 7 commissions et 4 groupes de travail.

Ceci afin d'aider les start-ups et les PME de cette filière à devenir des entreprises internationales performantes et capables de concevoir et développer rapidement de nouvelles innovations et les rendre accessibles in fine aux patients.

Du chercheur au patient, La HealthTech se mobilise

700 membres

+80 événements par an

+200 nouveaux membres en 2023

+100 rendez-vous institutionnels

Missions

- Représenter & défendre en portant la voix de la Healthtech auprès des institutions, des pouvoirs publics et du
- Coordonner & construire collectivement des positions sectorielles.

Flanders Bio

Contact [Become a member](#) [My flanders.bio](#)

≡ MENU **flanders.bio**

Welcome to flanders.bio

A dynamic, member-driven organisation dedicated to fostering innovation and growth in the life sciences ecosystem.

[Agrifood programme](#)

Programmes

We facilitate collaboration among members, empowering them to

[Health](#) [Agrifood](#)

Join our community

flanders.bio connects over 340 companies and research institutes in **biotech, health, and agrifoodtech**. We help our members to expand their network, build expertise and advocate a reputable global-impact ecosystem in life sciences.

Join our member network and enjoy the following benefits.

- Share your vacancies, news and events in our network
- Expand your network
- Access to trainings and events
- Go international
- In-depth technical and business knowledge in life sciences
- Enjoy exclusive member-to-member services

[Become a member](#)

Czech Bio

Sekce pro členy Login/Sign up CZ EN

CzechBio association of biotech companies Czech Republic

HOME ABOUT US NEWS MEMBERS CONTACT in f

CzechBio and media
Our Vision
Why become a member
Projects
Promo
Patents / Outputs

let's connect for the future of biotechnology

f in

we are supporting

 SIIIC Středočeské inovační centrum

 Life Sciences Baltics

 NLS DAYS 2025 nordic life science days 13-14 october gothenburg sweden a swedish event

 AgeingFit Accelerating innovation for healthy ageing

 MedFIT Fostering Innovation in medTech

 Biofit FOSTERING INNOVATION & TRANSFER

 ASGH The Voice in Innovation and Investment 引领·创新·投资

ASIA SUMMIT ON GLOBAL HEALTH 亚洲健康高峰论坛

17/5/2023 Hong Kong | In-person

18/5/2023 Online Only

 NutrEvent WHERE INNOVATION PARTNERSHIPS EMERGE

 KNOWLEDGE FOR GROWTH GETTING READY FOR A HEALTHY FUTURE

 D.B.T.

 BIOSPAIN Trade show and partnering 26-28 September 2023

 29th Global Dentists and Pediatric Dentistry Annual meeting

Sekce pro členy Login/Sign up CZ EN

CzechBio association of biotech companies Czech Republic

HOME ABOUT US NEWS MEMBERS CONTACT in f

Vision and mission CzechBio



Cluster mission

The mission statement of the cluster is to support and increase the competitiveness of its members. We will achieve this goal by realizing joint projects and linking business to the academical sphere. Members are being promoted to major world events abroad. CzechBio also supports and represents its members in defending their legitimate interests and requirements against all affected government authorities.

Cluster's vision

Cluster's vision is to create conditions for the development and economic growth of the entire biotechnology industry in the Czech Republic as one of the most important sectors of the future economy, thereby helping to increase the country's wealth.

Biotech Austria






BIOTECH AUSTRIA – LEADING INNOVATION AND GLOBAL LEADER IN BIOTECHNOLOGY





Biotechnology is a key contributor to innovation, cutting-edge technology and research, as well as to future prosperity. Biotechnology companies are furthermore attractive employers that offer fascinating global prospects to people from all backgrounds.



The biotechnology industry in Austria is one of the fastest developing sectors of the future, with high growth dynamics and international competitiveness.

BIOTECH AUSTRIA has been the Austrian biotechnology sector dedicated representative body since December 10, 2020. The overarching objectives of BIOTECH AUSTRIA are to bundle the interests of the industry in order to have a strong voice in politics and society, to improve the framework conditions and to realize synergy effects.






VISION & MISSION



 <h4>INTEREST REPRESENTATION</h4> <p>Establishment of an independent, specific representation of the interests of the Austrian biotechnology industry as a discussion partner for national and international decision-makers</p>	 <h4>EXCHANGE</h4> <p>Regular exchange of knowledge and experience between BIOTECH AUSTRIA members through lectures, seminars, workshops, taskforces and other events</p>
	



DATA & FACTS

 <p>60</p> <p>ORDINARY MEMBERS</p> <p>Show all</p>	 <p>9</p> <p>SUPPORTING MEMBERS</p> <p>Show all</p>	 <p>9</p> <p>ASSOCIATE MEMBERS</p> <p>Show all</p>
--	---	--

[DISPLAY MEMBERSHIP OPTIONS](#)



ORDINARY MEMBER	SUPPORTING MEMBER	ASSOCIATE MEMBER
<p>Any company (natural or legal person) active in all areas of biotechnology ("biotechnology company") as well as any person who is or has been active in biotechnology companies in Austria and can contribute to the promotion of biotechnology in Austria due to their special experience and knowledge can become a full member of the Association</p>	<p>An important goal of BIOTECH AUSTRIA is to influence the political and economic framework conditions. In order to achieve this goal, BIOTECH AUSTRIA invites all companies directly or indirectly associated with the biotech-industry to support the association's diverse activities in the form of a supporting membership</p>	<p>Associate members are industry stakeholders in the field of biotechnology who feel connected to the research-based SME sector and who promote the association's activities, particularly through cooperation in the scientific and academic field. These can be, for example, universities, scientific institutes and their associated organizations or other state institutions such as clusters</p>
<ul style="list-style-type: none">✓ Representation of interests✓ Access to networks✓ Access to partner associations✓ Special conditions with partners✓ Newsletter & specialist magazines	<ul style="list-style-type: none">✓ Name recognition✓ Logo display✓ Direct industry contacts✓ Your informational materials at our events	<ul style="list-style-type: none">✓ Industry contacts✓ Information exchange✓ Visibility, e.g., through a profile on the BIOTECH AUSTRIA website

Napirendi pontok

- MBSZ mérleg 2024
- Új generáció az MBSZ-ben: bemutatkozás és célok
- Felügyelőbizottsági poszt

